{
    "info": {
        "nct_id": "NCT03043313",
        "official_title": "MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer",
        "inclusion_criteria": "Inclusion Criteria\n\n* Histologically and/or cytologically documented adenocarcinoma of the colon or rectum that is metastatic and/or unresectable\n* Unless contraindicated, participants must have received and failed regimens containing the following agents: fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab, or ziv-aflibercept), and an anti-PD-(L)1 therapy (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins or is MSI-High.\n* Have progression of unresectable or metastatic CRC after the last systemic therapy, or be intolerant of last systemic therapy\n* Have RAS wild-type in primary or metastatic tumor tissue, based on expanded RAS testing\n* Willing and able to provide the most recently available tissue blocks obtained prior to treatment initiation. If archival tissue is not available, then a newly-obtained baseline biopsy of an accessible tumor\n* Have confirmed HER2-positive mCRC, as defined by having tumor tissue tested at a Clinical Laboratory Improvement Act (CLIA)-certified or International Organization for Standardization (ISO)-accredited laboratory, meeting at least one of the following criteria:\n\n  * HER2+ overexpression (3+ immunohistochemistry [IHC]) by an FDA-approved or Conformité Européene (CE)-marked HER2 ICH test\n  * HER2 2+ IHC is eligible if the tumor is amplified by an FDA-approved or CE-marked HER2 in situ hybridization assay (FISH or chromogenic in situ hybridization [CISH]))\n  * HER2 (ERBB2) amplification by CLIA-certified or ISO-accredited next generation sequencing (NGS) sequencing assay\n* Have radiographically measurable disease assessable by RECIST 1.1, with at least one site of disease that is measurable and that has not been previously irradiated; or, if the participant has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2\n* Life expectancy greater than 3 months\n* Have adequate hematological, hepatic, renal, coagulation, and cardiac function\n\nExclusion Criteria\n\n* Previous treatment with anti-HER2 targeting therapy\n* Previous treatment with any systemic anticancer therapy, non-central nervous system radiation, or experimental agent within 3 weeks of first dose of study treatment\n* Toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:\n\n  * Alopecia and neuropathy, which must have resolved to ≤ Grade 2\n  * Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence, and must have resolved completely\n  * Anemia, which must have resolved to ≤ Grade 2\n  * Decreased ANC, which must have resolved to ≤ Grade 2\n* Have clinically significant cardiopulmonary disease\n* Have known myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac surgery within 6 months prior to first dose of study treatment\n* Major surgical procedure, open biopsy, or significant traumatic injury ≤28 days prior to enrollment (≤56 days for hepatectomy, open thoracotomy, or major neurosurgery) or anticipation of need for major surgical procedure during the study\n* Serious, non-healing wound, ulcer, or bone fracture\n* Known to be positive for hepatitis B by surface antigen expression\n* Known to have active hepatitis C infection\n\n  * Exception for participants with a documented sustained virologic response of 12 weeks\n* Known to be positive for human immunodeficiency virus (HIV)\n* Subjects who are pregnant, breastfeeding, or planning a pregnancy\n* Inability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medications\n* Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a strong CYP2C8 or CYP3A4 inducer within 5 days prior to first dose of study treatment\n* History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.\n\n  * Exceptions are malignancies with a negligible risk of metastasis or death\n* Subjects with known active CNS metastasis\n\n  * Irradiated or resected lesions are permitted, provided the lesions are fully treated and inactive, subject is asymptomatic, and no steroids have been administered for at least 30 days\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Serious, non-healing wound, ulcer, or bone fracture",
            "criterions": [
                {
                    "exact_snippets": "Serious, non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "healing_status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serious, non-healing ... ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "healing_status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serious, non-healing ... bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "healing_status",
                            "expected_value": "non-healing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anemia, which must have resolved to ≤ Grade 2",
            "criterions": [
                {
                    "exact_snippets": "Anemia, which must have resolved to ≤ Grade 2",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with known active CNS metastasis",
            "criterions": [
                {
                    "exact_snippets": "known active CNS metastasis",
                    "criterion": "CNS metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known to have active hepatitis C infection",
            "criterions": [
                {
                    "exact_snippets": "Known to have active hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically and/or cytologically documented adenocarcinoma of the colon or rectum that is metastatic and/or unresectable",
            "criterions": [
                {
                    "exact_snippets": "Histologically and/or cytologically documented adenocarcinoma of the colon or rectum",
                    "criterion": "adenocarcinoma of the colon or rectum",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histologically documented",
                                "cytologically documented"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "adenocarcinoma of the colon or rectum that is metastatic and/or unresectable",
                    "criterion": "adenocarcinoma of the colon or rectum",
                    "requirements": [
                        {
                            "requirement_type": "metastatic_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Decreased ANC, which must have resolved to ≤ Grade 2",
            "criterions": [
                {
                    "exact_snippets": "Decreased ANC, which must have resolved to ≤ Grade 2",
                    "criterion": "decreased ANC",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence, and must have resolved completely",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure (CHF) ... must have been ≤ Grade 1 in severity ... must have resolved completely",
                    "criterion": "congestive heart failure (CHF)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "resolution_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have confirmed HER2-positive mCRC, as defined by having tumor tissue tested at a Clinical Laboratory Improvement Act (CLIA)-certified or International Organization for Standardization (ISO)-accredited laboratory, meeting at least one of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "confirmed HER2-positive mCRC",
                    "criterion": "HER2-positive metastatic colorectal cancer (mCRC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor tissue tested at a Clinical Laboratory Improvement Act (CLIA)-certified or International Organization for Standardization (ISO)-accredited laboratory",
                    "criterion": "tumor tissue testing laboratory certification/accreditation",
                    "requirements": [
                        {
                            "requirement_type": "certification/accreditation",
                            "expected_value": [
                                "CLIA-certified",
                                "ISO-accredited"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have radiographically measurable disease assessable by RECIST 1.1, with at least one site of disease that is measurable and that has not been previously irradiated; or, if the participant has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation",
            "criterions": [
                {
                    "exact_snippets": "radiographically measurable disease assessable by RECIST 1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one site of disease that is measurable and that has not been previously irradiated",
                    "criterion": "measurable disease site",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior irradiation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "if the participant has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation",
                    "criterion": "target lesion progression after prior radiation",
                    "requirements": [
                        {
                            "requirement_type": "prior irradiation to target lesion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "evidence of progression since radiation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known to be positive for human immunodeficiency virus (HIV)",
            "criterions": [
                {
                    "exact_snippets": "Known to be positive for human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with anti-HER2 targeting therapy",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with anti-HER2 targeting therapy",
                    "criterion": "anti-HER2 targeting therapy",
                    "requirements": [
                        {
                            "requirement_type": "previous treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have RAS wild-type in primary or metastatic tumor tissue, based on expanded RAS testing",
            "criterions": [
                {
                    "exact_snippets": "Have RAS wild-type in primary or metastatic tumor tissue, based on expanded RAS testing",
                    "criterion": "RAS mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wild-type"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medications",
            "criterions": [
                {
                    "exact_snippets": "Inability to swallow pills",
                    "criterion": "ability to swallow pills",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any significant gastrointestinal disease which would preclude the adequate oral absorption of medications",
                    "criterion": "gastrointestinal disease affecting oral absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing and able to provide the most recently available tissue blocks obtained prior to treatment initiation. If archival tissue is not available, then a newly-obtained baseline biopsy of an accessible tumor",
            "criterions": [
                {
                    "exact_snippets": "Willing and able to provide the most recently available tissue blocks obtained prior to treatment initiation",
                    "criterion": "provision of most recently available tissue blocks",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained prior to treatment initiation"
                        }
                    ]
                },
                {
                    "exact_snippets": "If archival tissue is not available, then a newly-obtained baseline biopsy of an accessible tumor",
                    "criterion": "newly-obtained baseline biopsy of an accessible tumor",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "baseline"
                        },
                        {
                            "requirement_type": "accessibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy greater than 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy greater than 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with any systemic anticancer therapy, non-central nervous system radiation, or experimental agent within 3 weeks of first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with any systemic anticancer therapy ... within 3 weeks of first dose of study treatment",
                    "criterion": "systemic anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous treatment with any ... non-central nervous system radiation ... within 3 weeks of first dose of study treatment",
                    "criterion": "non-central nervous system radiation",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous treatment with any ... experimental agent within 3 weeks of first dose of study treatment",
                    "criterion": "experimental agent",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have known myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac surgery within 6 months prior to first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "known myocardial infarction ... within 6 months prior to first dose of study treatment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina ... within 6 months prior to first dose of study treatment",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac or other vascular stenting ... within 6 months prior to first dose of study treatment",
                    "criterion": "cardiac or other vascular stenting",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "angioplasty ... within 6 months prior to first dose of study treatment",
                    "criterion": "angioplasty",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac surgery within 6 months prior to first dose of study treatment",
                    "criterion": "cardiac surgery",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known to be positive for hepatitis B by surface antigen expression",
            "criterions": [
                {
                    "exact_snippets": "Known to be positive for hepatitis B by surface antigen expression",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "surface antigen expression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a strong CYP2C8 or CYP3A4 inducer within 5 days prior to first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor",
                    "criterion": "use of strong CYP2C8 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "half-lives of the inhibitor"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have used a strong CYP2C8 or CYP3A4 inducer within 5 days prior to first dose of study treatment",
                    "criterion": "use of strong CYP2C8 inducer",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have used a strong CYP2C8 or CYP3A4 inducer within 5 days prior to first dose of study treatment",
                    "criterion": "use of strong CYP3A4 inducer",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have progression of unresectable or metastatic CRC after the last systemic therapy, or be intolerant of last systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "progression of unresectable or metastatic CRC after the last systemic therapy",
                    "criterion": "colorectal cancer (CRC) progression",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "progression"
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable or metastatic"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after the last systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerant of last systemic therapy",
                    "criterion": "tolerance to last systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HER2 (ERBB2) amplification by CLIA-certified or ISO-accredited next generation sequencing (NGS) sequencing assay",
            "criterions": [
                {
                    "exact_snippets": "HER2 (ERBB2) amplification",
                    "criterion": "HER2 (ERBB2) amplification",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "by CLIA-certified or ISO-accredited next generation sequencing (NGS) sequencing assay",
                    "criterion": "NGS assay certification/accreditation",
                    "requirements": [
                        {
                            "requirement_type": "certification/accreditation",
                            "expected_value": [
                                "CLIA-certified",
                                "ISO-accredited"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HER2+ overexpression (3+ immunohistochemistry [IHC]) by an FDA-approved or Conformité Européene (CE)-marked HER2 ICH test",
            "criterions": [
                {
                    "exact_snippets": "HER2+ overexpression (3+ immunohistochemistry [IHC])",
                    "criterion": "HER2 overexpression",
                    "requirements": [
                        {
                            "requirement_type": "immunohistochemistry score",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "+"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "by an FDA-approved or Conformité Européene (CE)-marked HER2 ICH test",
                    "criterion": "HER2 IHC test approval status",
                    "requirements": [
                        {
                            "requirement_type": "approval status",
                            "expected_value": [
                                "FDA-approved",
                                "CE-marked"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Irradiated or resected lesions are permitted, provided the lesions are fully treated and inactive, subject is asymptomatic, and no steroids have been administered for at least 30 days",
            "criterions": [
                {
                    "exact_snippets": "Irradiated or resected lesions are permitted, provided the lesions are fully treated and inactive",
                    "criterion": "irradiated or resected lesions",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "fully treated"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "inactive"
                        }
                    ]
                },
                {
                    "exact_snippets": "subject is asymptomatic",
                    "criterion": "symptom status",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no steroids have been administered for at least 30 days",
                    "criterion": "steroid administration",
                    "requirements": [
                        {
                            "requirement_type": "administration",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects who are pregnant, breastfeeding, or planning a pregnancy",
            "criterions": [
                {
                    "exact_snippets": "pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "planning a pregnancy",
                    "criterion": "pregnancy intention",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": "planning a pregnancy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unless contraindicated, participants must have received and failed regimens containing the following agents: fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab, or ziv-aflibercept), and an anti-PD-(L)1 therapy (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins or is MSI-High.",
            "criterions": [
                {
                    "exact_snippets": "participants must have received and failed regimens containing the following agents: fluoropyrimidine (e.g., 5-fluorouracil or capecitabine)",
                    "criterion": "prior fluoropyrimidine therapy",
                    "requirements": [
                        {
                            "requirement_type": "received_and_failed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participants must have received and failed regimens containing the following agents: ... oxaliplatin",
                    "criterion": "prior oxaliplatin therapy",
                    "requirements": [
                        {
                            "requirement_type": "received_and_failed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participants must have received and failed regimens containing the following agents: ... irinotecan",
                    "criterion": "prior irinotecan therapy",
                    "requirements": [
                        {
                            "requirement_type": "received_and_failed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participants must have received and failed regimens containing the following agents: ... an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab, or ziv-aflibercept)",
                    "criterion": "prior anti-VEGF monoclonal antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "received_and_failed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participants must have received and failed regimens containing the following agents: ... an anti-PD-(L)1 therapy (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins or is MSI-High",
                    "criterion": "prior anti-PD-(L)1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "received_and_failed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "tumor_mismatch_repair_status",
                            "expected_value": [
                                "deficient mismatch repair proteins",
                                "MSI-High"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions are malignancies with a negligible risk of metastasis or death",
            "criterions": [
                {
                    "exact_snippets": "malignancies with a negligible risk of metastasis or death",
                    "criterion": "malignancies",
                    "requirements": [
                        {
                            "requirement_type": "risk of metastasis",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "risk of death",
                            "expected_value": "negligible"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1",
                    "criterion": "toxicity related to prior cancer therapies",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have clinically significant cardiopulmonary disease",
            "criterions": [
                {
                    "exact_snippets": "clinically significant cardiopulmonary disease",
                    "criterion": "cardiopulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exception for participants with a documented sustained virologic response of 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "documented sustained virologic response of 12 weeks",
                    "criterion": "sustained virologic response",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HER2 2+ IHC is eligible if the tumor is amplified by an FDA-approved or CE-marked HER2 in situ hybridization assay (FISH or chromogenic in situ hybridization [CISH]))",
            "criterions": [
                {
                    "exact_snippets": "HER2 2+ IHC is eligible",
                    "criterion": "HER2 IHC score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": "2+"
                        }
                    ]
                },
                {
                    "exact_snippets": "if the tumor is amplified by an FDA-approved or CE-marked HER2 in situ hybridization assay (FISH or chromogenic in situ hybridization [CISH])",
                    "criterion": "HER2 gene amplification by in situ hybridization assay",
                    "requirements": [
                        {
                            "requirement_type": "amplification",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assay type",
                            "expected_value": [
                                "FDA-approved",
                                "CE-marked"
                            ]
                        },
                        {
                            "requirement_type": "assay method",
                            "expected_value": [
                                "FISH",
                                "CISH"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure, open biopsy, or significant traumatic injury ≤28 days prior to enrollment (≤56 days for hepatectomy, open thoracotomy, or major neurosurgery) or anticipation of need for major surgical procedure during the study",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure, open biopsy, or significant traumatic injury ≤28 days prior to enrollment",
                    "criterion": "major surgical procedure, open biopsy, or significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≤56 days for hepatectomy, open thoracotomy, or major neurosurgery",
                    "criterion": "hepatectomy, open thoracotomy, or major neurosurgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 56,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for major surgical procedure during the study",
                    "criterion": "anticipated need for major surgical procedure during the study",
                    "requirements": [
                        {
                            "requirement_type": "anticipated need",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alopecia and neuropathy, which must have resolved to ≤ Grade 2",
            "criterions": [
                {
                    "exact_snippets": "Alopecia ... must have resolved to ≤ Grade 2",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "neuropathy, which must have resolved to ≤ Grade 2",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.",
            "criterions": [
                {
                    "exact_snippets": "History of another malignancy within 3 years before the first dose of study drug",
                    "criterion": "history of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any evidence of residual disease from a previously diagnosed malignancy",
                    "criterion": "residual disease from previously diagnosed malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Exclusion Criteria",
            "criterions": []
        },
        {
            "line": "Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "* Have adequate hematological, hepatic, renal, coagulation, and cardiac function",
            "criterions": [
                {
                    "exact_snippets": "adequate hematological ... function",
                    "criterion": "hematological function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate hepatic ... function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate coagulation ... function",
                    "criterion": "coagulation function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... cardiac function",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}